CCL26. also known as eotaxin-3. is a chemokine belonging to the CC subfamily that plays a critical role in recruiting immune cells, particularly eosinophils, by binding to the CCR3 receptor. It is implicated in inflammatory and allergic conditions, including asthma, atopic dermatitis, and eosinophilic disorders. The CCL26 antibody is a laboratory tool designed to specifically detect, quantify, or neutralize CCL26 protein in biological samples. These antibodies are typically monoclonal or polyclonal, generated through immunization of host animals with recombinant CCL26 or peptide fragments. They are widely used in research applications such as ELISA, Western blotting, immunohistochemistry, and flow cytometry to study CCL26 expression patterns, signaling pathways, and its role in disease pathogenesis. Recent studies highlight CCL26's involvement in fibrotic diseases and cancer, expanding its clinical relevance. Antibodies targeting CCL26 also hold therapeutic potential, with investigations exploring their ability to block eosinophil migration in allergic inflammation. Validation of CCL26 antibodies includes specificity checks against related chemokines (e.g., CCL11. CCL24) and functional assays to confirm neutralization efficacy. As a biomarker, CCL26 levels are increasingly measured in clinical samples, underscoring the importance of reliable antibodies for diagnostic development.